NCT04252833View on ClinicalTrials.gov

Open-label, Crossover, Food Effect Study to Evaluate CT-044 in Healthy Human Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 18, 2020

Primary Completion Date

March 16, 2020

Study Completion Date

March 16, 2020

Conditions
Pain, AcuteAcute PainSurgeryNeuropathy
Interventions
DRUG

CT-044

CT-044 HCl is a reactive species decomposition accelerant

Trial Locations (1)

91105

Lotus Clinical Resarch,LLC, Pasadena

Sponsors

Collaborators (1)

CerSci Therapeutics
All Listed Sponsors
collaborator

CerSci Therapeutics

UNKNOWN

lead

Lotus Clinical Research, LLC

OTHER

NCT04252833 - Open-label, Crossover, Food Effect Study to Evaluate CT-044 in Healthy Human Volunteers | Biotech Hunter | Biotech Hunter